Esperion Therapeutics, Inc. (0IIM.L)
USD 1.53
(-5.33%)
USD 1.53
(-5.33%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 271.89 Million USD | 0.2% |
| 2022 | 228 Million USD | -21.64% |
| 2021 | 290.96 Million USD | -16.04% |
| 2020 | 346.55 Million USD | 43.52% |
| 2019 | 241.46 Million USD | 18.03% |
| 2018 | 204.58 Million USD | 21.07% |
| 2017 | 168.98 Million USD | 121.91% |
| 2016 | 76.15 Million USD | 52.18% |
| 2015 | 50.04 Million USD | 38.14% |
| 2014 | 36.22 Million USD | 59.17% |
| 2013 | 22.75 Million USD | 123.04% |
| 2012 | 10.2 Million USD | 0.39% |
| 2011 | 10.16 Million USD | 0.0% |
| 2002 | 29.23 Million USD | -0.32% |
| 2001 | 29.33 Million USD | 9.49% |
| 2000 | 26.78 Million USD | 129.25% |
| 1999 | 11.68 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 55.63 Million USD | -15.02% |
| 2024 Q1 | 65.46 Million USD | 3.65% |
| 2023 FY | 228.46 Million USD | 0.2% |
| 2023 Q4 | 63.15 Million USD | 2.69% |
| 2023 Q2 | 62.84 Million USD | 2.55% |
| 2023 Q1 | 61.28 Million USD | 7.19% |
| 2023 Q3 | 61.5 Million USD | -2.14% |
| 2022 Q4 | 57.17 Million USD | 5.68% |
| 2022 Q3 | 54.09 Million USD | -12.8% |
| 2022 Q2 | 62.04 Million USD | 13.42% |
| 2022 Q1 | 54.7 Million USD | -17.06% |
| 2022 FY | 228 Million USD | -21.64% |
| 2021 Q4 | 65.95 Million USD | 2.1% |
| 2021 Q3 | 64.59 Million USD | -9.52% |
| 2021 FY | 290.96 Million USD | -16.04% |
| 2021 Q1 | 89.01 Million USD | -14.01% |
| 2021 Q2 | 71.39 Million USD | -19.8% |
| 2020 Q2 | 82.66 Million USD | 8.41% |
| 2020 FY | 346.55 Million USD | 43.52% |
| 2020 Q1 | 76.25 Million USD | 27.21% |
| 2020 Q3 | 84.1 Million USD | 1.74% |
| 2020 Q4 | 103.51 Million USD | 23.08% |
| 2019 Q4 | 59.94 Million USD | -10.19% |
| 2019 FY | 241.46 Million USD | 18.03% |
| 2019 Q1 | 58.49 Million USD | -3.56% |
| 2019 Q2 | 56.28 Million USD | -3.78% |
| 2019 Q3 | 66.74 Million USD | 18.6% |
| 2018 Q3 | 50.56 Million USD | 8.78% |
| 2018 Q4 | 60.64 Million USD | 19.95% |
| 2018 FY | 204.58 Million USD | 21.07% |
| 2018 Q1 | 46.89 Million USD | 21.19% |
| 2018 Q2 | 46.48 Million USD | -0.88% |
| 2017 Q2 | 43.66 Million USD | 6.78% |
| 2017 Q1 | 40.88 Million USD | 39.62% |
| 2017 Q3 | 45.73 Million USD | 4.76% |
| 2017 FY | 168.98 Million USD | 121.91% |
| 2017 Q4 | 38.69 Million USD | -15.39% |
| 2016 FY | 76.15 Million USD | 52.18% |
| 2016 Q2 | 14.33 Million USD | -3.31% |
| 2016 Q1 | 14.82 Million USD | 12.0% |
| 2016 Q3 | 17.71 Million USD | 23.59% |
| 2016 Q4 | 29.28 Million USD | 65.34% |
| 2015 Q3 | 12.91 Million USD | 3.67% |
| 2015 Q4 | 13.23 Million USD | 2.44% |
| 2015 Q1 | 11.42 Million USD | 21.8% |
| 2015 Q2 | 12.46 Million USD | 9.08% |
| 2015 FY | 50.04 Million USD | 38.14% |
| 2014 Q3 | 9.7 Million USD | 4.82% |
| 2014 Q4 | 9.38 Million USD | -3.3% |
| 2014 Q2 | 9.25 Million USD | 17.29% |
| 2014 Q1 | 7.89 Million USD | -18.96% |
| 2014 FY | 36.22 Million USD | 59.17% |
| 2013 Q2 | 4.27 Million USD | 27.75% |
| 2013 Q1 | 3.34 Million USD | 54.81% |
| 2013 Q4 | 9.73 Million USD | 80.07% |
| 2013 Q3 | 5.4 Million USD | 26.57% |
| 2013 FY | 22.75 Million USD | 123.04% |
| 2012 FY | 10.2 Million USD | 0.39% |
| 2012 Q3 | 2.99 Million USD | 4.41% |
| 2012 Q2 | 2.86 Million USD | 30.8% |
| 2012 Q1 | 2.18 Million USD | 0.0% |
| 2012 Q4 | 2.16 Million USD | -27.76% |
| 2011 FY | 10.16 Million USD | 0.0% |
| 2003 Q3 | 6.45 Million USD | -20.8% |
| 2003 Q2 | 8.15 Million USD | 10.1% |
| 2003 Q1 | 7.4 Million USD | 14.5% |
| 2002 FY | 29.23 Million USD | -0.32% |
| 2002 Q4 | 6.46 Million USD | -12.41% |
| 2002 Q3 | 7.38 Million USD | -3.82% |
| 2002 Q2 | 7.67 Million USD | -0.45% |
| 2002 Q1 | 7.71 Million USD | 19.44% |
| 2001 Q2 | 8.19 Million USD | -1.81% |
| 2001 Q1 | 8.34 Million USD | 33.72% |
| 2001 FY | 29.33 Million USD | 9.49% |
| 2001 Q4 | 6.45 Million USD | -11.06% |
| 2001 Q3 | 7.25 Million USD | -11.43% |
| 2000 Q2 | 7.25 Million USD | 32.48% |
| 2000 Q1 | 5.47 Million USD | 0.0% |
| 2000 Q4 | 6.24 Million USD | -20.18% |
| 2000 FY | 26.78 Million USD | 129.25% |
| 2000 Q3 | 7.82 Million USD | 7.83% |
| 1999 FY | 11.68 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 84.43% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -2139.494% |
| Myriad Genetics, Inc. | 600.1 Million USD | 54.691% |
| Evolus, Inc. | 189.75 Million USD | -43.285% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 65.123% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 87.144% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 33.49% |
| uniQure N.V. | 285.08 Million USD | 4.626% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -387.655% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 1.377% |
| bluebird bio, Inc. | 240.23 Million USD | -13.181% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -460.589% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 84.895% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 26.238% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 36.421% |
| Dynavax Technologies Corporation | 219.14 Million USD | -24.072% |
| Editas Medicine, Inc. | 247.3 Million USD | -9.944% |
| FibroGen, Inc. | 398.11 Million USD | 31.704% |
| Geron Corporation | 70.44 Million USD | -285.993% |
| Blueprint Medicines Corporation | 722.86 Million USD | 62.386% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 86.756% |
| Illumina, Inc. | 3.81 Billion USD | 92.869% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 39.711% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -594.447% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 82.969% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -90.854% |
| Adicet Bio, Inc. | 152.03 Million USD | -78.835% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 80.02% |
| Insmed Incorporated | 949.26 Million USD | 71.357% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 50.705% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 75.041% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -508.72% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 48.603% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 99.33% |
| Waters Corporation | 943.51 Million USD | 71.183% |
| Zoetis Inc. | 2.76 Billion USD | 90.166% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 97.348% |
| Biogen Inc. | 5.2 Billion USD | 94.776% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -18.898% |
| Nektar Therapeutics | 190.9 Million USD | -42.427% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -169.667% |
| Perrigo Company plc | 1.52 Billion USD | 82.212% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 42.922% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -125.347% |
| Verastem, Inc. | 92.08 Million USD | -195.271% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 94.306% |
| Imunon, Inc. | 21.03 Million USD | -1192.874% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -1854.738% |
| Homology Medicines, Inc. | 9.87 Million USD | -2653.387% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 90.342% |
| OPKO Health, Inc. | 574.68 Million USD | 52.688% |
| Exelixis, Inc. | 1.58 Billion USD | 82.865% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 9.161% |
| TG Therapeutics, Inc. | 198.47 Million USD | -36.993% |
| Incyte Corporation | 1.19 Billion USD | 77.161% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 73.956% |